Literature DB >> 19285915

Resistance to antimalarial compounds: methods and applications.

Benoit Witkowski1, Antoine Berry, Françoise Benoit-Vical.   

Abstract

Considerable progress has been made in antimalarial research; however, much more effort is required to develop new antimalarials which overcome plasmodial resistance to clinically available drugs and limit the emergence of resistance. In particular, research must focus on understanding the mechanisms by which Plasmodium falciparum impedes the action of these drugs. In this review, we discuss the different in vitro and in vivo models used to adequately study resistance to antimalarial compounds. For each molecule studied, the best in vitro and/or in vivo model is highlighted with a detailed discussion of its validity in relation to field data on P. falciparum resistance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19285915     DOI: 10.1016/j.drup.2009.01.001

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  13 in total

1.  Human p38 mitogen-activated protein kinase inhibitor drugs inhibit Plasmodium falciparum replication.

Authors:  Michael J Brumlik; Standwell Nkhoma; Mark J Kious; George R Thompson; Thomas F Patterson; John J Siekierka; Tim J C Anderson; Tyler J Curiel
Journal:  Exp Parasitol       Date:  2011-02-19       Impact factor: 2.011

2.  Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism.

Authors:  Benoit Witkowski; Joel Lelièvre; María José López Barragán; Victor Laurent; Xin-zhuan Su; Antoine Berry; Françoise Benoit-Vical
Journal:  Antimicrob Agents Chemother       Date:  2010-02-16       Impact factor: 5.191

Review 3.  In vitro selection of Plasmodium falciparum drug-resistant parasite lines.

Authors:  Alexis Nzila; Leah Mwai
Journal:  J Antimicrob Chemother       Date:  2009-12-18       Impact factor: 5.790

Review 4.  CPP-ZFN: a potential DNA-targeting anti-malarial drug.

Authors:  Vikrant Nain; Shakti Sahi; Anju Verma
Journal:  Malar J       Date:  2010-09-16       Impact factor: 2.979

5.  Binding modes of 2,4-diaminoquinazoline and 2,4-diaminopteridine analogs to P. falciparum dihydrofolate reductase enzyme: Molecular docking studies.

Authors:  L Adane; P V Bharatam
Journal:  Indian J Pharm Sci       Date:  2010-05       Impact factor: 0.975

6.  Evidence for the contribution of the hemozoin synthesis pathway of the murine Plasmodium yoelii to the resistance to artemisinin-related drugs.

Authors:  Benoit Witkowski; Joel Lelièvre; Marie-Laure Nicolau-Travers; Xavier Iriart; Patrice Njomnang Soh; Fatima Bousejra-Elgarah; Bernard Meunier; Antoine Berry; Françoise Benoit-Vical
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

7.  In vitro resistance selections for Plasmodium falciparum dihydroorotate dehydrogenase inhibitors give mutants with multiple point mutations in the drug-binding site and altered growth.

Authors:  Leila S Ross; Francisco Javier Gamo; Maria José Lafuente-Monasterio; Onkar M P Singh; Paul Rowland; Roger C Wiegand; Dyann F Wirth
Journal:  J Biol Chem       Date:  2014-04-29       Impact factor: 5.157

8.  A framework for assessing the risk of resistance for anti-malarials in development.

Authors:  Xavier C Ding; David Ubben; Timothy N C Wells
Journal:  Malar J       Date:  2012-08-22       Impact factor: 2.979

9.  The Potential of β Carbolin Alkaloids to Hinder Growth and Reverse Chloroquine Resistance in Plasmodium falciparum.

Authors:  Zaid O Ibraheem; Roslaini Abdul Majid; Sabariah Mohd Noor; Hasidah Mohd Sidek; Rusliza Basir
Journal:  Iran J Parasitol       Date:  2015 Oct-Dec       Impact factor: 1.012

Review 10.  Plasmodium falciparum: multifaceted resistance to artemisinins.

Authors:  Lucie Paloque; Arba P Ramadani; Odile Mercereau-Puijalon; Jean-Michel Augereau; Françoise Benoit-Vical
Journal:  Malar J       Date:  2016-03-09       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.